Dr. Reddy's Launches Generic Lamictal

Following FDA approval of its abbreviated new drug application, or ANDA, Dr. Reddy's Laboratories (NYSE: RDY  ) announced today that it launched its lamotrigine extended-release tablets, the generic version of GlaxoSmithKline's Lamictal. 

Lamotrigine is an anticonvulsant used to treat epilepsy and bipolar disorders. The generic-drug maker said it launched the drug on June 25 and the extended-release tablets are available in dosages of 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg in 30-count bottles.

Dr. Reddy's Labs quotes IMS Health in noting the branded drug had domestic sales of approximately $300.5 million for the trailing 12-month period ending in April.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2512032, ~/Articles/ArticleHandler.aspx, 9/30/2014 7:56:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement